Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01587027
Other study ID # GQ01 DARPA
Secondary ID
Status Completed
Phase Phase 1
First received April 16, 2012
Last updated May 12, 2014
Start date December 2011
Est. completion date February 2012

Study information

Verified date May 2014
Source Poudre Valley Health System
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This safety study is the first in a series of studies testing the application of the combination of aminophylline and methazolamide.


Description:

After successful completion of this safety trial, our goal will be to evaluate the safety of this combination in healthy individuals exposed to hypoxia and exercise. Subsequently, an efficacy study will clarify whether this drug combination improves physical and mental functions in human subjects under high altitude conditions.


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date February 2012
Est. primary completion date February 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria:

- Subjects must be healthy non-smoking adult male and female volunteers between the ages of 18 and 40 years, with a BMI of 18-30 kg/m2 and weighting at least 150 lbs. Women who are of childbearing potential, must, if sexually active, must agree to use appropriate contraceptive measures for the duration of the study and for one (1) month afterwards.

- Subjects must agree not to donate blood, plasma, platelets, or any other blood components during the study and for 4 weeks after the last dose.

Exclusion Criteria:

- History or manifestation of clinically significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematologic or other medical disorders.

- Serious mental or physical illness within the past year.

- History of clinically significant illness within 4 weeks prior to Day 1.

- History of allergic reaction, hypersensitivity or idiosyncratic reaction to any of the products administered during the study, including allergy to any sulfa or sulfonamide derivatives.

- Use of any of the following:

- Any concomitant medication. Subjects who have received any prescribed or non-prescribed (over-the-counter [OTC]) systemic medication, topical medications, or herbal supplements within 14 days from Day 1. St. John's Wort (hypericin) must not have been taken for at least 30 days prior to Period 1, Day 1.

- Any drugs, foods or substances known to be strong inhibitors or strong inducers of CYP enzymes (also known as cytochrome P450 enzymes); especially CYP 1A2, or Pgp within 30 days prior to Period 1, Day 1.

- Currently abusing drugs or alcohol or with a history of drug or alcohol abuse within the past two years.

- Positive results on screening tests for drugs of abuse, cotinine or alcohol at screening or the pre-dose assessment at check-in.

- Clinically significant ECG abnormality, in the opinion of the Investigator.

- Use of tobacco products or other nicotine-containing products (including smoking cessation aids, such as gums or patches) with in 14 days of screening and throughout hospitalization.

- Subjects of childbearing potential who are pregnant (as based on test results) or are breast feeding.

- Has taken any other investigational drug during the 30 days prior to the screening visit or is currently participating in another investigational clinical trial.

- Subjects who have made any significant donation (including plasma) or have had a significant loss of blood within 30 days prior to Period 1, Day 1.

Receipt of a transfusion or any blood products within 30 days prior to Period 1, Day 1.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Drug:
Aminophylline
Aminophylline dosage form-tablet dosage-500mg
Methazolamide
Methazolamide dosage form-tablet dosage-250mg
Aminophylline and Methazolamide
Aminophylline 500mg orally and Methazolamide 250mg orally

Locations

Country Name City State
United States Medical Center of the Rockies Loveland Colorado

Sponsors (3)

Lead Sponsor Collaborator
Poudre Valley Health System Defense Advanced Research Projects Agency, University of Colorado, Denver

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse Events. Adverse event data was evaluated for incidence and severity for 6 days. 6 days. Yes
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01182792 - Chronic Mountain Sickness, Systemic Vascular Function N/A
Completed NCT00952302 - Study of the Effects of Iron Levels on the Lungs at High Altitude N/A
Completed NCT04075565 - The Psychophysiological Effect of Simulated and Terrestrial Altitude N/A
Completed NCT01187108 - Study of Cobalt's Role in Excessive Erythrocytosis Among High Altitude Dwellers in Cerro de Pasco, Peru Phase 1/Phase 2
Not yet recruiting NCT06129825 - Pharmacologic Induction of Tolerance for Hypoxia & Hypothermia
Completed NCT02463357 - Three New Ideas to Protect Special Forces From the Stress of High Altitude Phase 4

External Links